PGGM Investments Acquires 8,382 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

PGGM Investments lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 87,067 shares of the biopharmaceutical company’s stock after purchasing an additional 8,382 shares during the period. PGGM Investments’ holdings in Gilead Sciences were worth $7,053,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in GILD. Clearbridge Investments LLC grew its holdings in shares of Gilead Sciences by 179.0% during the third quarter. Clearbridge Investments LLC now owns 4,543,985 shares of the biopharmaceutical company’s stock worth $340,526,000 after purchasing an additional 2,915,141 shares during the last quarter. abrdn plc grew its holdings in shares of Gilead Sciences by 89.0% during the fourth quarter. abrdn plc now owns 3,764,107 shares of the biopharmaceutical company’s stock worth $304,930,000 after purchasing an additional 1,772,887 shares during the last quarter. International Assets Investment Management LLC bought a new stake in shares of Gilead Sciences during the fourth quarter worth $133,584,000. AEGON ASSET MANAGEMENT UK Plc bought a new stake in shares of Gilead Sciences during the fourth quarter worth $63,971,000. Finally, Bailard Inc. boosted its holdings in Gilead Sciences by 9,100.7% in the third quarter. Bailard Inc. now owns 722,345 shares of the biopharmaceutical company’s stock valued at $54,133,000 after acquiring an additional 714,494 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $73.18, for a total value of $146,360.00. Following the sale, the insider now owns 100,936 shares of the company’s stock, valued at approximately $7,386,496.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on GILD shares. UBS Group decreased their price target on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Friday. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target on the stock in a report on Wednesday. Oppenheimer reissued an “outperform” rating and issued a $105.00 target price on shares of Gilead Sciences in a research note on Friday, April 19th. Finally, Royal Bank of Canada cut their target price on Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating on the stock in a research note on Friday. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $83.87.

Gilead Sciences Stock Up 0.2 %

Shares of NASDAQ GILD traded up $0.15 during mid-day trading on Friday, reaching $65.42. 12,382,425 shares of the company’s stock were exchanged, compared to its average volume of 6,443,315. The firm has a market capitalization of $81.45 billion, a price-to-earnings ratio of 181.72, a PEG ratio of 1.17 and a beta of 0.19. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. The business has a fifty day simple moving average of $71.28 and a 200 day simple moving average of $76.25. Gilead Sciences, Inc. has a twelve month low of $64.63 and a twelve month high of $87.86.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The company had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. Gilead Sciences had a return on equity of 23.08% and a net margin of 1.76%. Gilead Sciences’s revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the firm posted $1.37 earnings per share. As a group, equities analysts expect that Gilead Sciences, Inc. will post 3.82 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 4.71%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s dividend payout ratio is presently 855.56%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.